Hard to Treat Diseases, Incorporated Files U.S. Provisional Patent Application
DELRAY BEACH, Fla., Dec 17, 2004 (BUSINESS WIRE) -- Hard to Treat Diseases,
Incorporated (HTTD) (Pink Sheets: HTDS) Announces Filing of U.S. Provisional
Application for Methods and Compositions for Treatment of Viral Infections.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion
of Tubercin(R).
The provisional application discloses the testing results of HTTD's proprietary
formulation for the treatment of viral infections, which was recently filed on
behalf of HTTD as a result of ongoing testing and research conducted on various
compounds and substances that HTTD owns, controls or has the licensed rights to.
Testing results could not be released until the provisional application was
filed due to the confidential and sensitive nature of the information. Recently,
the major focus of HTTD, its research team and patent attorneys has been on
preparing and filing the provisional application.
Testing results to date have been finalized and incorporated in the provisional
application. An overview of the results will be released in the very near
future. The testing documents comprise a valuable asset that has been created
for HTTD. This asset, along with the underlying testing documents, is
confidential, not available to competitors, and HTTD has taken extraordinary
steps to maintain its confidential nature and contents.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion
of Tubercin(R). In addition to our proprietary formulation and various
compounds, referenced in the provisional application, HTTD also acquired and
holds the worldwide (except Korea) marketing rights and license to manufacture,
use, market, distribute and otherwise to commercialize Tubercin(R), which
includes Tubercin(R)'s issued patents in the following countries:
Japanese patent: issued 6/12/98
United States patent: issued 8/14/01
European patent: issued 8/13/03
Canada patent: issued 5/11/04
Mr. Colm J. King, CEO of HTTD, commented, "HTTD's value and goals have been
strengthened with the provisional application. We will continue to aggressively
advance the testing of Tubercin(R) in the U.S.; in addition to aggressively
advance the testing of our proprietary formulation and other compounds and
substances, contained in the provisional application, in the U.S.; and make
strategic decisions with the goal of being involved in negotiations with major
drug firms within 18 months."
Mr. King added, "Testing and evaluation results are an essential interim step in
obtaining the FDA approval necessary to market a product. Our testing and
research has been supervised and conducted in U.S. FDA approved laboratories by
experienced medical and scientific professionals. HTTD will vigorously enforce
its lawful rights, which includes defending its advantageous business
relationships and negotiations that are instrumental in establishing a solid
reputation and significant presence in our field and attaining the goals of
benefiting patients and HTTD's shareholders."
HTTD is currently involved in litigation regarding the rights to Tubercin(R).
Additional information and details regarding the litigation can be viewed on our
website at: htdsotc.com
SOURCE: Hard to Treat Diseases, Incorporated
CONTACT: Hard to Treat Diseases, Incorporated
Colm J. King, 561-272-6900
www.htdsotc.com
. |
